Tirzepatide side effects: the real list, not the marketing list

The marketing version of tirzepatide side effects is: "some nausea, most adjust, worth it." The real list is longer. Here it is.

Common, expected, usually manageable

Nausea. 30-40% of users at some point, usually during titration. Mitigated by eating smaller meals, avoiding greasy food for a day or two after injection, staying hydrated. For most users it resolves after 2-4 weeks at a stable dose.

Diarrhea or constipation. 15-25%. The drug slows gastric emptying, which swings both directions depending on the user. Adequate fiber and water helps. Magnesium supplementation for constipation. For persistent diarrhea, pause and consult the prescribing clinician.

Reduced appetite. This is the desired effect. It is also a side effect. Users sometimes drop below their basal caloric needs by accident because they are not hungry. Protein floor (1.6 to 2.2 g/kg body weight) matters to protect muscle mass during weight loss.

Fatigue in the first 2-4 weeks. Partially from eating less, partially from the drug itself. Usually resolves.

Injection-site reactions. Mild redness, small bump, itch. Usually resolves within a day. Rotate injection sites (abdomen, thigh, upper arm).

Sulfur burps. Odd but common. The drug changes GI motility and gas profile. Resolves for most users after first few weeks.

Less common, more serious

Vomiting. Distinguishes from nausea by actually happening. 5-10% of users. If it persists or prevents hydration, pause the drug and contact your clinician.

Acute pancreatitis. Rare (<1%), but real. Symptoms: severe upper abdominal pain, often radiating to the back, not relieved by usual measures. Emergency room immediately. This is a label warning on every GLP-1 drug.

Gallbladder disease. Gallstones, gallbladder inflammation. More likely in users losing weight rapidly. Symptoms: right upper abdominal pain, especially after fatty meals. Not an emergency unless severe, but get it evaluated.

Allergic reaction. Rare. Rash, swelling, difficulty breathing = 911. This is true for any injectable.

Hypoglycemia when combined with other diabetes drugs. Not typically an issue for non-diabetic users. If you are on insulin or sulfonylureas, this requires careful dose coordination with your clinician.

Rare, serious, important to know about

Medullary thyroid cancer risk. The FDA label includes a boxed warning based on rat data showing thyroid C-cell tumors at high doses. Human relevance is uncertain and long-term human data so far have not shown a clear signal. But the warning is there, and it is a hard contraindication for:

• Personal history of medullary thyroid carcinoma
• Family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia type 2 (MEN 2)

If any of those apply to you, tirzepatide is not for you. This is not a risk-reward tradeoff. It is a do-not-use line.

Kidney impact in dehydrated users. The drug can worsen dehydration because of GI symptoms. In users with existing kidney impairment or on medications that affect kidney function (certain blood pressure drugs, NSAIDs), this can cause acute kidney injury. Keep hydration up. Tell your clinician about all medications.

Diabetic retinopathy progression. Some studies in diabetic users have shown acute worsening of retinopathy during rapid glycemic improvement. This is a diabetic-user issue, not a weight-loss-only-user issue, but worth knowing.

What happens in rehab trials (SURMOUNT and SURPASS)

Discontinuation rates for intolerable side effects in the big trials: roughly 5-7% at 5 mg, 7-10% at 15 mg. Placebo arms saw 1-3% discontinuation. The drug is better tolerated than older obesity drugs (e.g., phentermine/topiramate), worse tolerated than cardiovascular drugs (e.g., statins).

What to do on day one

1. Have anti-nausea measures ready. Ginger, small meals, hydration. Some users get a prescription for ondansetron from their clinician. 2. Inject in the evening. If nausea hits, you sleep through some of it. 3. Stay hydrated. 2-3 liters of water per day, more if sweating. 4. Know your contraindications. If any of the thyroid-cancer criteria apply, do not start. 5. Have a clinician's phone number. Not for day one, for the bad day that might happen later.

The honest summary

Most users tolerate tirzepatide. Some do not. A few experience serious adverse events. The drug is not without cost, but for users who meet the indication and have no contraindications, the benefit-risk math usually works out.

The people who should not take it are well-defined. The people who should are more nuanced. A clinical conversation is the right venue for that conversation.

If you want our match

Take the quiz. Two minutes. We email you within 24 to 48 hours with a match that makes sense for your situation.